The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Levetiracetam in the treatment of epilepsy
Open accessAbstract
Epilepsy is a common chronic disorder that requires long-term antiepileptic drug therapy. Approximately one half of patients fail the initial antiepileptic drug and about 35% are refractory to medical therapy, highlighting the continued need for more effective and better tolerated drugs. Levetiracetam is an antiepileptic drug marketed since 2000. Its novel mechanism of action is modulation of synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A in the brain. Its pharmacokinetic advantages include rapid and almost complete absorption, minimal insignificant binding to plasma protein, absence of enzyme induction, absence of interactions with other drugs, and partial metabolism outside the liver. The availability of an intravenous preparation is yet another advantage. It has been demonstrated effective as adjunctive therapy for refractory partial-onset seizures, primary generalized tonic-clonic seizures, and myoclonic seizures of juvenile myoclonic epilepsy. In addition, it was found equivalent to controlled release carbamazepine as first-line therapy for partial-onset seizures, both in efficacy and tolerability. Its main adverse effects in randomized adjunctive trials in adults have been somnolence, asthenia, infection, and dizziness. In children, the behavioral adverse effects of hostility and nervousness were also noted. Levetiracetam is an important addition to the treatment of epilepsy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Early Identification of Refractory Epilepsy
Kwan, P., & Brodie, M. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002033420503 · Cited by 5,204
Cited by
Biologically active γ-lactams: synthesis and natural sources
Caruano, J., Muccioli, G. G., & Robiette, R. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob01349j · Cited by 436
Child development following in utero exposure: Levetiracetam vs sodium valproate
Shallcross, R., Bromley, R. L., Irwin, B., Bonnett, L. J., Morrow, J., & Baker, G. A. (2011) · Neurology · doi:10.1212/wnl.0b013e3182088297 · Cited by 161
Levetiracetam Mechanisms of Action: From Molecules to Systems
Contreras-García, I. J., Cárdenas-Rodríguez, N., Romo-Mancillas, A., Bandala, C., Zamudio, S. R., Gómez-Manzo, S., Hernández-Ochoa, B., Mendoza-Torreblanca, J. G., & Pichardo-Macías, L. A. (2022) · Pharmaceuticals · doi:10.3390/ph15040475 · Cited by 131
Brigo, F., Ausserer, H., Tezzon, F., & Nardone, R. (2013) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2013.03.010 · Cited by 67
Metadata
- Authors
- Abou-Khalil, B.
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2008-06
- Volume
- 4
- Issue
- 3
- Pages
- 507
- ISSN
- 1176-6328 (ISSN-L)
- OpenAlex
- W2089791879
- Cited by
- 232
- References
- 2
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Levetiracetam in the treatment of epilepsy. https://app.cochat.ai/papers/10.2147/ndt.s2937
- The paper
- Abou-Khalil, B. (2008). Levetiracetam in the treatment of epilepsy. Neuropsychiatric Disease and Treatment. https://doi.org/10.2147/ndt.s2937
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.